Reify Health today announced a $220 million Series C funding round led by Coatue Management, joined by ICONIQ Growth and Adams Street Partners, as well as existing investors Sierra Ventures and Battery Ventures. This latest funding, which brings the company's valuation to $2.2 billion, underscores Reify Health's success in dramatically shortening clinical trial timelines.

Reify Health paves the way to faster, predictable, and more accessible clinical trials. Through its business entities, StudyTeam and Care Access, the company provides best-in-class clinical optimization software, with a focus on effective enrollment, and transformative clinical trial infrastructure that delivers research directly to more healthcare providers, communities, and patients wherever they are. Through partnerships with top biopharma companies, leading healthcare organizations, and thousands of research sites worldwide, Reify Health eliminates delays in drug development one trial at a time. To find out how Reify Health makes clinical research better, faster, and more collaborative, visit www.reifyhealth.com.